Stina Syvänen
Stina Syvänen
Researcher, Public Health and Caring Sciences
Verified email at pubcare.uu.se
Title
Cited by
Cited by
Year
On the rate and extent of drug delivery to the brain
M Hammarlund-Udenaes, M Fridén, S Syvänen, A Gupta
Pharmaceutical research 25 (8), 1737-1750, 2008
3882008
Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport
S Syvänen, Ö Lindhe, M Palner, BR Kornum, O Rahman, B Långström, ...
Drug metabolism and disposition 37 (3), 635-643, 2009
2852009
Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer’s disease
D Sehlin, XT Fang, L Cato, G Antoni, L Lannfelt, S Syvänen
Nature communications 7 (1), 1-11, 2016
962016
Advances in PET imaging of P-glycoprotein function at the blood-brain barrier
S Syvänen, J Eriksson
ACS chemical neuroscience 4 (2), 225-237, 2013
722013
Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood–brain barrier can be studied with PET
S Syvänen, G Blomquist, M Sprycha, AU Höglund, M Roman, O Eriksson, ...
Neuroimage 32 (3), 1134-1141, 2006
702006
Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor
G Hultqvist, S Syvänen, XT Fang, L Lannfelt, D Sehlin
Theranostics 7 (2), 308, 2017
642017
Pharmacokinetic consequences of active drug efflux at the blood–brain barrier
S Syvänen, R Xie, S Sahin, M Hammarlund-Udenaes
Pharmaceutical research 23 (4), 705-717, 2006
612006
Blood–brain barrier penetration of zolmitriptan—modelling of positron emission tomography data
M Bergström, R Yates, A Wall, M Kågedal, S Syvänen, B Långström
Journal of pharmacokinetics and pharmacodynamics 33 (1), 75-91, 2006
552006
Delineating amyloid plaque associated neuronal sphingolipids in transgenic Alzheimer’s disease mice (tgArcSwe) using MALDI imaging mass spectrometry
I Kaya, D Brinet, W Michno, S Syvänen, D Sehlin, H Zetterberg, ...
ACS chemical neuroscience 8 (2), 347-355, 2017
432017
Specific uptake of an amyloid-β protofibril-binding antibody-tracer in AβPP transgenic mouse brain
K Magnusson, D Sehlin, S Syvänen, MM Svedberg, O Philipson, ...
Journal of Alzheimer's Disease 37 (1), 29-40, 2013
392013
[11 C] phenytoin revisited: synthesis by [11 C] CO carbonylation and first evaluation as a P-gp tracer in rats
J Verbeek, J Eriksson, S Syvänen, M Labots, ECM de Lange, RA Voskuyl, ...
EJNMMI research 2 (1), 1-11, 2012
382012
(R)-[C-11] PK11195 brain uptake as a biomarker of inflammation and antiepileptic drug resistance: Evaluation in a rat epilepsy model
RM Bogdanovic, S Syvanen, C Michler, V Russmann, J Eriksson, ...
Neuropharmacology 85, 104-112, 2014
372014
Pharmacokinetics of P‐glycoprotein inhibition in the rat blood‐brain barrier
S Syvänen, A Hooker, O Rahman, H Wilking, G Blomquist, B Långström, ...
Journal of pharmaceutical sciences 97 (12), 5386-5400, 2008
372008
Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs
S Syvanen, M Hammarlund-Udenaes
Current topics in medicinal chemistry 10 (17), 1799-1809, 2010
362010
(R)-[11 C] Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus
S Syvänen, G Luurtsema, CFM Molthoff, AD Windhorst, MC Huisman, ...
BMC medical imaging 11 (1), 1-16, 2011
352011
Probing amyloid‐β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry
L Carlred, W Michno, I Kaya, P Sjövall, S Syvänen, J Hanrieder
Journal of neurochemistry 138 (3), 469-478, 2016
342016
Altered GABAA receptor density and unaltered blood–brain barrier transport in a kainate model of epilepsy: an in vivo study using 11C-flumazenil and PET
S Syvänen, M Labots, Y Tagawa, J Eriksson, AD Windhorst, ...
Journal of Nuclear Medicine 53 (12), 1974-1983, 2012
322012
A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils–a new concept for neuroimaging
S Syvänen, XT Fang, G Hultqvist, SR Meier, L Lannfelt, D Sehlin
Neuroimage 148, 55-63, 2017
282017
[11C] quinidine and [11C] laniquidar PET imaging in a chronic rodent epilepsy model: impact of epilepsy and drug-responsiveness
S Syvänen, V Russmann, J Verbeek, J Eriksson, M Labots, C Zellinger, ...
Nuclear medicine and biology 40 (6), 764-775, 2013
262013
Effect on [11C]DASB binding after tranylcypromine‐induced increase in serotonin concentration: Positron emission tomography studies in monkeys and rats
P Lundquist, M Roman, S Syvänen, P Hartvig, G Blomquist, ...
Synapse 61 (6), 440-449, 2007
262007
The system can't perform the operation now. Try again later.
Articles 1–20